Search hospitals > Iowa > Fort Dodge
Trinity Regional Medical Center
Claim this profileFort Dodge, Iowa 50501
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Tumors
Conducts research for Adenocarcinoma
Conducts research for Lung Cancer
108 reported clinical trials
2 medical researchers
Summary
Trinity Regional Medical Center is a medical facility located in Fort Dodge, Iowa. This center is recognized for care of Cancer, Breast Cancer, Tumors, Adenocarcinoma, Lung Cancer and other specialties. Trinity Regional Medical Center is involved with conducting 108 clinical trials across 249 conditions. There are 2 research doctors associated with this hospital, such as Joshua Lukenbill and Robert J. Behrens.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
Joshua LukenbillMedical Oncology and Hematology Associates-Des Moines4 years of reported clinical research
Expert in Cancer
Expert in Tumors
140 reported clinical trials
215 drugs studied
Robert J. BehrensIowa Methodist Medical Center4 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
43 reported clinical trials
97 drugs studied
Clinical Trials running at Trinity Regional Medical Center
Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Melanoma
Gastric Cancer
Bladder Cancer
Cutaneous Melanoma
Esophageal Cancer
Esophageal Adenocarcinoma
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Cognitive Training
for Breast Cancer Survivors
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
Recruiting1 award N/A5 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Trinity Regional Medical Center?
Trinity Regional Medical Center is a medical facility located in Fort Dodge, Iowa. This center is recognized for care of Cancer, Breast Cancer, Tumors, Adenocarcinoma, Lung Cancer and other specialties. Trinity Regional Medical Center is involved with conducting 108 clinical trials across 249 conditions. There are 2 research doctors associated with this hospital, such as Joshua Lukenbill and Robert J. Behrens.